# Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

> **NCT02175654** · PHASE2 · TERMINATED · sponsor: **Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)** · enrollment: 15 (actual)

## Conditions studied

- Colorectal Neoplasms
- Metastatic Disease

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02175654
- **Lead sponsor:** Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The trial was prematurely closed due to lack of accrual
- **Last updated:** 2017-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175654, "Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02175654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*